London: The first human trials of an Ebola vaccine developed using the same technology as the AstraZeneca Covid jab began on Thursday at the University of Oxford. The vaccine "ChAdOx1 biEBOV" will be tested on 26 volunteers ranging in age from 18 to 55 years old in order to determine its safety and immunogenicity. According to a statement from the Jenner Institute at the University of Oxford, "we are conducting a clinical trial of a new Ebola vaccine called 'ChAdOx1 biEBOV,' which is designed to target two of the deadliest species of Ebola-causing viruses."

It will test the vaccine's efficacy and the immune response it elicits in healthy adult volunteers against the Zaire and Sudan Ebola virus species. The vaccine is based on the ChAdOx1 vaccine technology, which was previously used to develop the Oxford/AstraZeneca Covid-19 vaccine with great success. It is made with adenovirus, which is a genetically modified version of the common cold virus that cannot replicate in humans. Participants in the trial will be followed for six months, with results expected in the second quarter of 2022.

Ebola is a severe, often fatal illness that is transmitted to humans by wild animals and then spreads through direct contact with infected people's blood, secretions, organs, or other bodily fluids.

France issues warning to people under the age of 30 not to take the Moderna vaccine

Indonesia to begin giving Covid booster doses, post 50-pc populace fully inoculated

Health: The bill to fluoridate drinking water has passed its third reading